New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:16 EDTVRTXVertex downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Vertex Pharmaceuticals to Neutral with an $85 price target following yesterday's rally. The firm believes share are appropriately valued at current levels.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 7, 2015
10:30 EDTVRTXOptions with decreasing implied volatility
Subscribe for More Information
10:10 EDTVRTXOptions with decreasing implied volatility
Subscribe for More Information
July 6, 2015
08:03 EDTVRTXVertex price target raised to $158 from $150 at Leerink
Leerink raised its price target for Vertex to $158 after the FDA approved Orkambi to treat cystic fibrosis patients 12 years and older who are homozygous for the F508del CFTR mutation. The firm views the $259,000 annual pricing as in line with consensus expectations after assuming a larger gross to net discount as compared to Kalydeco. Leerink keeps an Outperform rating on the stock.
07:43 EDTVRTXVertex price target raised to $160 from $131 at Baird
Subscribe for More Information
06:13 EDTVRTXVertex price target raised to $161 from $146 at Piper Jaffray
Subscribe for More Information
July 2, 2015
16:28 EDTVRTXOn The Fly: Top stock stories for Thursday
Subscribe for More Information
14:51 EDTVRTXVertex expects payers to provide 'broad access' for Orkambi
Subscribe for More Information
14:50 EDTVRTXVertex to resume trading at 3:00 PM ET
Subscribe for More Information
14:42 EDTVRTXVertex says 'too early to comment' on international Orkambi pricing
Subscribe for More Information
14:33 EDTVRTXVertex sets Orkambi price at $259,000, sees delivery to pharmacies 'within days'
Following today's confirmation from Vertex that Orkambi has received FDA approval, the company held a conference call providing an update on the drug. Vertex remarked that it is "ready to launch this medicine." Vertex will offer a co-pay assistance program for the drug, with certain eligibility criteria. Company believes it can achieve a similar patient cost situation as Kalydeco. Sets price of Orkambi at $259,000 per year. Expects delivery to pharmacy network "within days."
13:52 EDTVRTXVertex to hold a conference call
Subscribe for More Information
13:47 EDTVRTXVertex confirms FDA approval of ORKAMBI
Vertex Pharmaceuticals announced that the U.S. FDA approved ORKAMBI, the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. It is only indicated for these patients, who can be identified with a genetic test. People with two copies of the F508del mutation represent the largest group of people with CF. Of the 30,000 people in the United States with CF, approximately 8,500 ages 12 and older have two copies of the F508del mutation. ORKAMBI will be available for shipment to specialty pharmacies in the United States within days.
12:47 EDTVRTXVertex to return to profitability with approval, says Piper Jaffray
Subscribe for More Information
12:00 EDTVRTXVertex receives FDA approval for Orkambi
Subscribe for More Information
11:50 EDTVRTXVertex trading halted, pending news
Subscribe for More Information
June 30, 2015
07:32 EDTVRTXVertex should get Orkambi approval by Monday or sooner, says Piper Jaffray
Subscribe for More Information
June 29, 2015
15:28 EDTVRTXVertex management to meet with UBS
Subscribe for More Information
07:47 EDTVRTXCerulean appoints Stuart A. Arbuckle to board of directors, effective June 26
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use